Characteristics | Number |
---|---|
Total | 25 (100.0%) |
Age (years, median) | 73.7 (range 29.6–88.2) |
ECOG performance status | |
0 | 1 (4.0%) |
1 | 19 (76.0%) |
2 | 4 (16.0%) |
3 | 1 (4.0%) |
FIGO stage (2018) | |
I | 1 (4.0%) |
II | 10 (40.0%) |
III | 9 (36.0%) |
IV | 5 (20.0%) |
Pathology | |
Squamous cell carcinoma | 20 (80.0%) |
Adenocarcnoma | 3 (12.0%) |
Poorly differentiated carcinoma | 2 (8.0%) |
Pelvic organ invasion | |
Yes | 4 (16.0%) |
No | 21 (84.0%) |
Pelvic lymph node metastasis | |
Yes | 9 (36.0%) |
No | 16 (64.0%) |
Paraaortic lymph node metastasis | |
Yes | 6 (24.0%) |
No | 19 (76.0%) |
Distant metastasis | |
Yes | 2 (8.0%) |
No | 23 (92.0%) |
Concurrent chemotherapy | |
Yes | 17 (68.0%) |
No | 8 (32.0%) |
Consolidation chemotherapy | |
Yes | 4 (16.0%) |
No | 21 (84.0%) |